Stock Events

Recordati SpA 

€50.75
79
-€0.65-1.26% Today

Statistics

Day High
51.05
Day Low
50.75
52W High
48.62
52W Low
34.6
Volume
1,540
Avg. Volume
22,258
Mkt Cap
9.81B
P/E Ratio
-
Dividend Yield
2.33%
Dividend
1.18

Upcoming

Dividends

2.33%Dividend Yield
10Y Growth
14.34%
5Y Growth
4.32%
3Y Growth
1.05%
1Y Growth
2.8%

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0.34
0.46
0.57
0.69
Expected EPS
0.69
Actual EPS
0.59

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0KBS.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap244.62B
Novartis is a global healthcare company that competes with Recordati in the pharmaceuticals sector, particularly in the development and marketing of prescription medications.
Pfizer
PFE
Mkt Cap163.88B
Pfizer is a large pharmaceutical company that competes directly with Recordati in the development and distribution of drugs across various therapeutic areas.
Merck &
MRK
Mkt Cap323.59B
Merck & Co. is a leading pharmaceutical company that competes with Recordati in the research, development, and marketing of drugs, especially in the areas of cardiovascular diseases.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie competes with Recordati in the pharmaceutical industry, particularly in the development of therapies for diseases in areas like immunology and oncology, which may overlap with Recordati's product offerings.
GSK
GSK
Mkt Cap81.16B
GlaxoSmithKline is a global healthcare company that competes with Recordati in the pharmaceutical and healthcare sector, including the development of medications for various diseases.
Astrazeneca
AZN
Mkt Cap245.69B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company that competes with Recordati in the development and marketing of prescription medicines, particularly in the cardiovascular, renal, and metabolism therapeutic areas.
Sanofi
SNY
Mkt Cap130B
Sanofi is a global healthcare leader that competes with Recordati in the pharmaceutical sector, offering a wide range of prescription medicines, vaccines, and over-the-counter healthcare products.
Bristol-Myers Squibb
BMY
Mkt Cap82.02B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Recordati in the discovery, development, and delivery of medicines in areas such as cardiovascular, oncology, and immunoscience.
Johnson & Johnson
JNJ
Mkt Cap360.71B
Johnson & Johnson is a diversified healthcare giant that competes with Recordati not only in the pharmaceutical sector but also in consumer health products and medical devices.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.57B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Recordati in the generic drug market and in the development of specialty pharmaceuticals.

About

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
Show more...
CEO
Dr. Robert Koremans M.D.
Employees
4455
Country
IT
ISIN
IT0003828271
WKN
000A0EABR

Listings